Methyl-deficient diet promotes colitis and SIRT1-mediated endoplasmic reticulum stress.

Background: Methyl donor deficiency (MDD) aggravates experimental colitis in rats and increases endoplasmic reticulum (ER) stress through decreased sirtuin 1 (SIRT1) in neuronal cells and myocardium. ER stress plays a key role in IBD pathogenesis.

Aim: We investigated whether the influence of MDD on colitis resulted from an ER stress response triggered by decreased SIRT1 expression.

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.

Background And Aims: About one-third of inflammatory bowel disease (IBD) patients still require surgery. A growing number of them receive anti-tumor necrosis factor (TNF) therapy before surgery. The present meta-analysis studied the risk of postoperative complications in IBD patients treated with anti-TNF.

Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review.

Background: Nonadherence to medications may affect disease outcomes. The aim of this article was to review methods of assessment, prevalence, and predictors of nonadherence to anti-tumor necrosis factor therapy in inflammatory bowel diseases (IBD).

Methods: Studies were identified through the electronic database of MEDLINE (up to January 2012) and the annual meetings of Digestive Disease Week, the American College of Gastroenterology, the United European Gastroenterology Week, and the European Crohn's and Colitis Organization.

Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.

Background & Aims: Little is known about the long-term efficacy of infliximab for patients with fistulizing perianal Crohn's disease. We evaluated outcomes and predictors of outcomes in these patients.

Methods: The medical records of 156 patients treated with infliximab for fistulizing perianal Crohn's disease at 2 referral centers from 1999 through 2010 were reviewed through September 2011.

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.

We report the findings and outputs of an international expert opinion process to develop a definition of early Crohn's disease (CD) that could be used in future disease-modification trials. Nineteen experts on inflammatory bowel diseases held an international expert opinion meeting to discuss and agree on a definition for early CD to be used in disease-modification trials. The process included literature searches for the relevant basic-science and clinical evidence.

5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey.

Background And Aim: 5-Aminosalicylates (ASA) are widely used in inflammatory bowel disease (IBD). Nephrotoxicity has been described in some IBD patients treated with 5-ASA. Whether physicians managing these patients are monitoring renal function in daily practice is unknown.

Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn's disease.

Background: No definite conclusions can be drawn from available data on the accuracy of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to assess disease activity in Crohn's disease.

Aims: Plasma sTREM-1 levels were correlated with disease activity markers in Crohn's disease.

Methods: 191 consecutive patients from a single referral centre (Nancy IBD cohort) were prospectively enrolled between June 1, 2005 and December 12, 2008.

Ulcerative colitis as a progressive disease: the forgotten evidence.

In the management of Crohn's disease, earlier aggressive treatment is becoming accepted as a strategy to prevent or retard progression to irreversible bowel damage. It is not yet clear, however, if this same concept should be applied to ulcerative colitis. Hence, we review herein the long-term structural and functional consequences of this latter disease.

Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics.

Background: The cumulative incidence of colectomy and the impact of 5-aminosalicylates (5-ASA), azathioprine, and antitumor necrosis factor (TNF) treatment on the long-term need for surgery are unknown in ulcerative colitis (UC) in the era of biologics.

Methods: This was an observational study of a referral center cohort. The cumulative incidence of UC-related colectomy was estimated using the Kaplan-Meier method.

Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience.

Background: Cystitis is the most common genitourinary complication in Crohn's disease (CD). We assessed the prevalence of and risk factors for urinary tract infections (UTI) in inflammatory bowel diseases (IBD).

Methods: Among the 1173 IBD patients of the "Nancy IBD cohort" seen between January 1, 2000 and December 31, 2009, 56 hospitalized patients had 76 documented UTI.

Update on Crohn's disease and ulcerative colitis.

The 6th European Crohn's and Colitis Organisation Congress took place in Dublin, Ireland, on the occasion of the 10th European Crohn's and Colitis Organisation anniversary. This key annual event attracted a record number of participants and presented updated information in the field of inflammatory bowel disease in children and adults. The extensive program combined the original basic scientific program that dealt with pathogenesis and new therapeutic targets, while the clinical program focused on the possibility of optimizing current therapies, the importance of mucosal healing and features of inflammatory bowel disease-related cancer.

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.

The objective of this study was to review loss of response and need for adalimumab dose intensification in adult and pediatric patients with Crohn's disease. Studies were identified through the electronic databases of MEDLINE and the annual meetings of Digestive Disease Week, of the United European Gastroenterology Week, and of the American College of Gastroenterology and the European Crohn's and Colitis Organization meetings. Studies evaluating loss of efficacy and/or need for dose intensification were included.

Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience.

Background: We evaluated adherence to adalimumab therapy in Crohn's disease (CD).

Methods: This was an observational multicenter study conducted in four French university hospitals between April 4, 2008 and January 1, 2010. Patients were systematically asked, at each clinical visit, whether or not they delayed or missed an injection of adalimumab over the past 3 months.